SAM-DTA: a sequence-agnostic model for drug-target binding affinity prediction

Machine Learning for Sequence and Structure-Based Protein-Ligand Interaction Prediction

Developing new drugs is too expensive and time -consuming. Accurately predicting the interaction between drugs and targets will likely change how the drug is discovered. Machine learning-based protein-ligand interaction prediction has demonstrated significant potential. In this paper, computational methods, focusing on sequence and structure to study protein-ligand interactions, are examined. Therefore, this paper starts by presenting an overview of the data sets applied in this area, as well as the various approaches applied for representing proteins and ligands. Then, sequence-based and structure-based classification criteria are subsequently utilized to categorize and summarize both the classical machine learning models and deep learning models employed in protein-ligand interaction studies. Moreover, the evaluation methods and interpretability of these models are proposed. Furthermore, delving into the diverse applications of protein-ligand interaction models in drug research is presented. Lastly, the current challenges and future directions in this field are addressed.

TEFDTA: a transformer encoder and fingerprint representation combined prediction method for bonded and non-bonded drug-target affinities

MOTIVATION

The prediction of binding affinity between drug and target is crucial in drug discovery. However, the accuracy of current methods still needs to be improved. On the other hand, most deep learning methods focus only on the prediction of non-covalent (non-bonded) binding molecular systems, but neglect the cases of covalent binding, which has gained increasing attention in the field of drug development.

RESULTS

In this work, a new attention-based model, A Transformer Encoder and Fingerprint combined Prediction method for Drug-Target Affinity (TEFDTA) is proposed to predict the binding affinity for bonded and non-bonded drug-target interactions. To deal with such complicated problems, we used different representations for protein and drug molecules, respectively. In detail, an initial framework was built by training our model using the datasets of non-bonded protein-ligand interactions. For the widely used dataset Davis, an additional contribution of this study is that we provide a manually corrected Davis database. The model was subsequently fine-tuned on a smaller dataset of covalent interactions from the CovalentInDB database to optimize performance. The results demonstrate a significant improvement over existing approaches, with an average improvement of 7.6% in predicting non-covalent binding affinity and a remarkable average improvement of 62.9% in predicting covalent binding affinity compared to using BindingDB data alone. At the end, the potential ability of our model to identify activity cliffs was investigated through a case study. The prediction results indicate that our model is sensitive to discriminate the difference of binding affinities arising from small variances in the structures of compounds.

AVAILABILITY AND IMPLEMENTATION

The codes and datasets of TEFDTA are available at https://github.com/lizongquan01/TEFDTA.

AffinityVAE: A multi-objective model for protein-ligand affinity prediction and drug design

In the prediction of protein-ligand affinity, the traditional methods require a large amount of computing resources, and have certain limitations in predicting and simulating the structural changes. Although employing data-driven approaches can yield favorable outcomes in deep learning, it entails a lack of interpretability. Some methods may require additional structural information or domain knowledge to support the interpretation, which may limit their applicability. This paper proposes an affinity variational autoencoder (AffinityVAE) using interaction feature mapping and a variational autoencoder, which consists of a multi-objective model capable of end-to-end affinity prediction and drug discovery. In this study, the limitations of affinity prediction in terms of interpretability are tackled by proposing the concept of a protein-ligand interaction feature map. This increases the diversity and quantity of protein-ligand binding data by designing an adaptive autoencoder of target chemical properties to generate new ligands similar to known ligands and adding them to the original training set. AffinityVAE is then retrained using this extended training set to further validate the protein-ligand binding affinity prediction. Comparisons were conducted between the AffinityVAE and recent methods to demonstrate the high efficiency of the proposed model. The experimental results show that AffinityVAE has very high prediction performance, and it has the potential to enhance the diversity and the amount of protein-ligand binding data, which promotes the drug development.